6aH-6,14a-(Iminoethano)naphth[2,1-b]acridine-2,6a-diol, 5,6,7,14-tetrahydro-17-methyl-, (6R,6aS,14aR)-

Request For Quotation
6aH-6,14a-(Iminoethano)naphth[2,1-b]acridine-2,6a-diol, 5,6,7,14-tetrahydro-17-methyl-, (6R,6aS,14aR)- Suppliers list
Company Name: TargetMol Chemicals Inc.  
Tel: +1-781-999-5354; +1-00000000000
Email: marketing@targetmol.com
Company Name: Jinan Jiuli Biotechnology Co. , Ltd.  
Tel: 15865264761
Email: 486064515@qq.com
Company Name: TargetMol Chemicals Inc.  
Tel: 4008200310 15002144251
Email: marketing@tsbiochem.com
Company Name: Shanghai Tachizaki Biomedical Research Center  
Tel: 18014399201
Email: sales@chemlab-tachizaki.com
Company Name: Nantong QuanYi Biotechnology Co., Ltd  
Tel: 0513-66337626 18051384581
Email: sales@chemhifuture.com
6aH-6,14a-(Iminoethano)naphth[2,1-b]acridine-2,6a-diol, 5,6,7,14-tetrahydro-17-methyl-, (6R,6aS,14aR)- Basic information
Product Name:6aH-6,14a-(Iminoethano)naphth[2,1-b]acridine-2,6a-diol, 5,6,7,14-tetrahydro-17-methyl-, (6R,6aS,14aR)-
Synonyms:6aH-6,14a-(Iminoethano)naphth[2,1-b]acridine-2,6a-diol, 5,6,7,14-tetrahydro-17-methyl-, (6R,6aS,14aR)-;KNT 127;KNT127;KNT-127;KNT 127,KNT127
CAS:1256921-89-7
MF:C24H24N2O2
MW:372.46
EINECS:
Product Categories:
Mol File:1256921-89-7.mol
6aH-6,14a-(Iminoethano)naphth[2,1-b]acridine-2,6a-diol, 5,6,7,14-tetrahydro-17-methyl-, (6R,6aS,14aR)- Structure
6aH-6,14a-(Iminoethano)naphth[2,1-b]acridine-2,6a-diol, 5,6,7,14-tetrahydro-17-methyl-, (6R,6aS,14aR)- Chemical Properties
Melting point 250-254 °C (decomp)
Boiling point 594.7±50.0 °C(Predicted)
density 1.38±0.1 g/cm3(Predicted)
pka9.87±0.40(Predicted)
form Solid
color Off-white to light yellow
Safety Information
MSDS Information
6aH-6,14a-(Iminoethano)naphth[2,1-b]acridine-2,6a-diol, 5,6,7,14-tetrahydro-17-methyl-, (6R,6aS,14aR)- Usage And Synthesis
DescriptionKNT-127 is a δ-Opioid receptor agonist.
UsesKNT-127 is a potent δ-opioid receptor agonist that crosses the blood-brain barrier (BBB). KNT-127 is highly selective to the δ receptor, with Ki values of 0.16, 21.3 and 153 nM for δ, μ and κ receptors, respectively. KNT-127 increases the release of dopamine and L-glutamate in the striatum, nucleus accumbens, and prefrontal cortex. KNT-127 has analgesic, antidepressant and antianxiety activities[1][2][3][4][5].
in vivo

KNT-127 (10 mg/kg; Subcutaneous injection; Single dose) exerts antidepressant effects through Akt-mTORC1-p70S6K signaling pathway in medial prefrontal cortex and ERK-mTORC1-p70S6K signaling pathway in amygdala[1].
KNT-127 (20 mg/kg; Intraperitoneal injection; 38 days) has an improved effect in mouse models of depression[2].
KNT-127 (5 mg/kg; Subcutaneous injection; Single dose) has an improved effect in mouse models of chronic migraine[3].

Animal Model:Chronic vicarious social defeat stress (cVSDS) treated male C57BL/6J mice[2]
Dosage:20 mg/kg
Administration:Intraperitoneal injection (i.p.); 38 days
Result:Improved decreased social interaction behaviors and increased serum corticosterone levels.
Suppressed decreases in the hippocampal newborn neuron survival rate.
Inhibited cVSDS-induced overactivation of microglia.
Animal Model:Nitroglycerin treated C57BL6/J mice[3]
Dosage:5 mg/kg
Administration:Subcutaneous injection (s.c.); Single dose
Result:Did not alter mechanical responses in vehicle pre-treated mice.
Inhibited Nitroglycerin-induced chronic allodynia.
IC 50δ Opioid Receptor/DOR; mTORC1
References[1] Yoshioka T, et al. Delta opioid receptor agonists activate PI3K-mTORC1 signaling in parvalbumin-positive interneurons in mouse infralimbic prefrontal cortex to exert acute antidepressant-lie effects. Mol Psychiatry. 2024 Dec 6. DOI:10.1038/s41380-024-02814-z
[2] Yoshioka T, et al. KNT-127, a selective delta opioid receptor agonist, shows beneficial effects in the hippocampal dentate gyrus of a chronic vicarious social defeat stress mouse model. Neuropharmacology. 2023 Jul 1;232:109511. DOI:10.1016/j.neuropharm.2023.109511
[3] Bertels Z, et al. A non-convulsant delta-opioid receptor agonist, KNT-127, reduces cortical spreading depression and nitroglycerin-induced allodynia. Headache. 2021 Jan;61(1):170-178. DOI:10.1111/head.14019
[4] Nagase H, et al. Design and synthesis of KNT-127, a δ-opioid receptor agonist effective by systemic administration. Bioorg Med Chem Lett. 2010;20(21):6302-6305. DOI:10.1016/j.bmcl.2010.08.083
[5] Tanahashi S, et al. Novel δ1-receptor agonist KNT-127 increases the release of dopamine and L-glutamate in the striatum, nucleus accumbens and median pre-frontal cortex. Neuropharmacology. 2012;62(5-6):2057-2067. DOI:10.1016/j.neuropharm.2012.01.005
6aH-6,14a-(Iminoethano)naphth[2,1-b]acridine-2,6a-diol, 5,6,7,14-tetrahydro-17-methyl-, (6R,6aS,14aR)- Preparation Products And Raw materials
Tag:6aH-6,14a-(Iminoethano)naphth[2,1-b]acridine-2,6a-diol, 5,6,7,14-tetrahydro-17-methyl-, (6R,6aS,14aR)-(1256921-89-7) Related Product Information
(S)-4-(4-((2-(3,5-diMethylphenyl)pyrrolidin-1-yl)Methyl)phenoxy)-3-fluorobenzaMide Naloxegol Oxalate DAGO BETA-ENDORPHIN HUMAN SYNTHETIC Mianserin hydrochloride Sinomenine